• Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency in target engagement assays against KAT6 and KAT7, and ~350-to-2,000-fold selectivity over the KAT5 and KAT8 paralogs
  • KAT6/7 dual inhibitor demonstrates greater monotherapy efficacy and durability than KAT6 selective inhibitors in preclinical CDX and PDX models
  • Multiple combination opportunities with IDE574 and IDEAYA's proprietary pipeline
  • Potential first-in-class and best-in-class preclinical profile will be presented at AACR 2026